Silybum marianum peptide-rich fraction alleviates acute liver injury by inhibiting TRAF3/NIK/NF-κB and is associated with changes in gut microbiota composition.
- 1International School of Mongolian Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.
- 2Clinical Laboratory, The Second Affiliated Hospital, Inner Mongolia Medical University, Hohhot, China.
- 3Inner Mongolia Bioactive Peptide Engineering Laboratory, Clinical Medical Research Center, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Abstract
Acute liver injury (ALI) is a severe and prevalent condition that can progress to irreversible liver damage and failure. This study aimed to investigate the prophylactic hepatoprotective potential of Silybum marianum peptides (SMP) in ALI and elucidate its underlying mechanisms. Using a carbon tetrachloride (CCl₄)-induced ALI mouse model, we evaluated the dose-dependent effects of SMP. Additionally, we explored the modulatory effects of SMP on the NF-κB pathway, gut microbiota composition, and metabolite profiles. The role of SMP in the TRAF3/NIK/NF-κB signaling axis was further validated in a NIK-overexpressing Hepa1-6 cell model. Our results demonstrated that 14-day SMP administration did not significantly affect body weight, fasting blood glucose levels, or liver and spleen weights, and no significant difference in serum ALT activity was observed. Notably, SMP (200 mg/kg) significantly alleviated CCl₄-induced liver injury, as evidenced by enhanced hepatic antioxidant capacity, reduced expression of proinflammatory cytokines, and attenuated immune cell infiltration. Furthermore, SMP was associated with changes in gut microbiota composition and community structure in CCl₄-induced ALI mice. Mechanistically, SMP suppressed the TRAF3/NIK/NF-κB pathway. These findings highlight SMP as a promising candidate for the prevention of CCl₄-induced ALI, acting through multimodal mechanisms involving anti-inflammatory, antioxidant, and gut microbiota-associated pathways.
Related
- Statement of Retraction: Baicalin regulates macrophages polarization and alleviates myocardial ischaemia/reperfusion injury via inhibiting JAK/STAT pathway.
- Crocin alleviates renal fibrosis through inhibiting mitochondrial dysfunction via regulating HOXD8/PGC‑1α pathways
- BMI1 Overexpression Alleviates Metabolic Syndrome‐Related Liver Injury by Inhibiting the Activation of the METTL3/AHNAK Axis
- A Self-Developed IL-6Rα Nanobody Alleviates Experimental Autoimmune Uveitis by Inhibiting Th1 and Th17 Cells
- Baicalin alleviates X-ray radiation-induced intestinal injury by inhibiting GPX4 mediated ferroptosis
BibTeX
@article{ananda2026silybum,
title = {{Silybum marianum peptide-rich fraction alleviates acute liver injury by inhibiting TRAF3/NIK/NF-κB and is associated with changes in gut microbiota composition.}},
author = {Ananda and Wenyan Han and Khurelbaatar Nyamdavaa and Xian Li and Tsend-Ayush Damba and Xiulan Su},
journal = {Frontiers in pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1915943},
url = {https://europepmc.org/article/MED/42898363},
note = {CC BY},
}
RIS
TY - JOUR
TI - Silybum marianum peptide-rich fraction alleviates acute liver injury by inhibiting TRAF3/NIK/NF-κB and is associated with changes in gut microbiota composition.
AU - Ananda
AU - Wenyan Han
AU - Khurelbaatar Nyamdavaa
AU - Xian Li
AU - Tsend-Ayush Damba
AU - Xiulan Su
PY - 2026
DA - 2026/10/05
JO - Frontiers in pharmacology
DO - 10.3389/fphar.2026.1915943
UR - https://europepmc.org/article/MED/42898363
AB - Acute liver injury (ALI) is a severe and prevalent condition that can progress to irreversible liver damage and failure. This study aimed to investigate the prophylactic hepatoprotective potential of Silybum marianum peptides (SMP) in ALI and elucidate its underlying mechanisms. Using a carbon tetrachloride (CCl₄)-induced ALI mouse model, we evaluated the dose-dependent effects of SMP. Additionally, we explored the modulatory effects of SMP on the NF-κB pathway, gut microbiota composition, and metabolite profiles. The role of SMP in the TRAF3/NIK/NF-κB signaling axis was further validated in a NIK-overexpressing Hepa1-6 cell model. Our results demonstrated that 14-day SMP administration did not significantly affect body weight, fasting blood glucose levels, or liver and spleen weights, and no significant difference in serum ALT activity was observed. Notably, SMP (200 mg/kg) significantly alleviated CCl₄-induced liver injury, as evidenced by enhanced hepatic antioxidant capacity, reduced expression of proinflammatory cytokines, and attenuated immune cell infiltration. Furthermore, SMP was associated with changes in gut microbiota composition and community structure in CCl₄-induced ALI mice. Mechanistically, SMP suppressed the TRAF3/NIK/NF-κB pathway. These findings highlight SMP as a promising candidate for the prevention of CCl₄-induced ALI, acting through multimodal mechanisms involving anti-inflammatory, antioxidant, and gut microbiota-associated pathways.
SN - 1663-9812
ER -